1. Home
  2. Analysis
  3. Ispaghula
  4. Humalog

Ispaghula and Humalog drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ispaghula (blond psyllium) and Humalog (insulin lispro recombinant). Common drug interactions include hallucination among females and angina pectoris among males.

The phase IV clinical study analyzes what interactions people have when they take Ispaghula and Humalog. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Ispaghula?

Ispaghula has active ingredients of blond psyllium. eHealthMe is studying from 737 Ispaghula users. Check the latest studies of Ispaghula.

What is Humalog?

Humalog has active ingredients of insulin lispro recombinant. It is often used in diabetes. eHealthMe is studying from 137,127 Humalog users. Check the latest studies of Humalog.

On Jul, 11, 2026

11 people who take Ispaghula and Humalog together, and have interactions are studied.

Ispaghula and Humalog drug interactions.

What are the common drug interactions of Ispaghula and Humalog, by gender? *:

female:

  1. Hallucination (an experience involving the perception of something not present)
  2. Poor quality sleep
  3. Anaemia (lack of blood)
  4. Hypocoagulable state (abnormality of blood coagulation that increases the risk of thrombosis)
  5. Subcutaneous haematoma (collection of blood outside the blood vessels on the skin)

male:

  1. Angina pectoris (chest pain due to ischemia of the heart muscle)
  2. Bronchopneumonia (inflammation of the lungs, arising in the bronchi or bronchioles)
  3. Haemostasis (stopping of bleeding)

What are the common drug interactions of Ispaghula and Humalog, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Hallucination (an experience involving the perception of something not present)
  2. Poor quality sleep
  3. Anaemia (lack of blood)
  4. Hypocoagulable state (abnormality of blood coagulation that increases the risk of thrombosis)
  5. Subcutaneous haematoma (collection of blood outside the blood vessels on the skin)

What are the existing conditions these people have? *

  1. Asthma: 6 people, 54.55%
  2. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 18.18%
  3. Chest Pain: 2 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Ispaghula and Humalog?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ispaghula and Humalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ispaghula:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Humalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ispaghula and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Humalog and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on blond psyllium and insulin lispro recombinant (the active ingredients of Ispaghula and Humalog, respectively), and Ispaghula and Humalog (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.